M&A Deal Summary |
|
|---|---|
| Date | 2019-08-06 |
| Target | Currenta OHG |
| Sector | Chemicals |
| Buyer(s) | Macquarie Infrastructure and Real Assets |
| Sellers(s) |
Bayer
LANXESS |
| Deal Type | Divestiture |
| Deal Value | 3.5B EUR |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Infrastructure |
|---|---|
| PE ASSETS | 119.0B USD |
| Size | Mega |
| Type | Sector Focused |
Macquarie Infrastructure and Real Assets (MIRA) is a global investor in infrastructure, real estate, agriculture, and energy assets. MIRA's infrastructure practice looks to acquire businesses such as transportation, water and energy utilities, and waste management. MIRA's real estate practice looks to acquire and develop retail, commercial, residential and industrial properties. MIRA's agriculture team looks to operate and develop agriculture businesses and farmland. MIRA's energy team seeks opportunities in upstream energy and upstream energy-related assets and businesses in the US and Canada. Macquarie Infrastructure and Real Assets is headquartered in London with additional offices throughout the world.
| DEAL STATS | # |
|---|---|
| Overall | 13 of 20 |
| Sector (Chemicals) | 1 of 1 |
| Type (Divestiture) | 3 of 4 |
| Country (Germany) | 1 of 2 |
| Year (2019) | 3 of 7 |
| Size (of disclosed) | 2 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-03-15 |
Brussels Airport
Brussels, Belgium Brussels Airport manages the Brussels airport, a European airport handling 25.7 million passengers and 732,000 tonnes of freight annually. Brussels Airport links the European capital with 248 destinations worldwide and is served by 80 different airlines. Brussels Airport is based in Brussels, Belgium. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-07 |
Ocean Breeze Energy KG
Bremen, Germany Ocean Breeze Energy GmbH & Co. KG is the owner and operator of the wind farm, BARD Offshore 1 (BO1), about 100 km off the German North Sea coast. BO1, Germany's first commercial and currently the most powerful offshore wind farm, has been fully connected to the electricity grid since September 2013. With a capacity of 80 wind turbines of the 5-megawatt class, a rated output of 400 megawatts will be achieved - equivalent to the electricity requirement of more than 400,000 households. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1863 |
| Sector | Life Science |
| Employees | 99,349 |
| Revenue | 50.7B EUR (2022) |
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer was founded in 1863 and is based in Leverkusen, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 13 of 22 |
| Sector (Chemicals) | 5 of 6 |
| Type (Divestiture) | 9 of 18 |
| Country (Germany) | 8 of 12 |
| Year (2019) | 3 of 4 |
| Size (of disclosed) | 2 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-07-22 |
Dr. Scholl s Shoes
St. Louis, Missouri, United States Dr. Scholl's Shoes is a provider of foot care brand that has an over 110-year heritage with brand equity in the foot care category. Dr. Scholl's Shoes is based in St. Louis, Missouri. |
Sell | $585M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-08 |
BlueRock Therapeutics
Cambridge, Massachusetts, United States BlueRock Therapeutics LLC is a cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce native cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. |
Buy | $1.0B |
LANXESS is a German specialty chemicals company. The company is currently represented at 52 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of plastics, rubber, intermediates and specialty chemicals. LAXNESS was founded in 1863 and is based in Cologne, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector (Chemicals) | 2 of 3 |
| Type (Divestiture) | 2 of 3 |
| Country (Germany) | 2 of 3 |
| Year (2019) | 1 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-09-25 |
Chemtura
Philadelphia, Pennsylvania, United States Chemtura Corp. is a specialty chemicals company. Chemtura offers a number of products used in the transportation, energy & electronics, and agriculture sectors. Chemtura was formed in 1900 and is based in Philadelphia, Pennsylvania. |
Buy | $2.5B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-11-13 |
Lanxess Organometallics
Cologne, Germany Lanxess Organometallics GmbH is a provider of organotin catalysts, organotin specialties, and intermediates product lines. Lanxess Organometallics is based in Cologne, Germany. |
Sell | - |
